Pharmasset, Inc. (VRUS)

A springtime mystery of the low valuation of Pharmasset stock has given way to an autumn enigma of the near triple in share price since May. No one seems to be able to make up their minds about this company. I've tracked them up and down on CAPS but I always seem to bail out of my picks leaving 50% of potential points on the table. The true valuation of Pharmasset stock remains the Schrodinger's cat of baby biotech. While the current share price is still far below the all-time high of 35 seen after the initial encouraging phase I data for R7128, the market cap of 630M isn't way below the high of 740M due to multiple dilutive financings. Strong results for INFORM-1 came after the share price had already tripled and have only served, in my opinion, to delay an inevitable return of the share price to the low teens during the long wait for phase II data for R7128.

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!